Systemic Immune-inflammation Index (SII) Predicts Pathological Complete Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer

OBJECTIVE To determine the relationship between inflammatory markers and pathological complete response (pCR) in patients with locally advanced rectal cancer (LARC), who received neoadjuvant chemoradiotherapy (NACRT). STUDY DESIGN Descriptive study. PLACE AND DURATION OF Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Oncology Training Research Hospital, Ankara, Turkey from January 2014 to June 2020. METHODOLOGY Patients older than 18 years age, underwent NACRT a diagnosis LARC, had no disease or drug-use that could affect parameters, were included Inflammatory indices (neutrophil-to-lymphocyte ratio-NLR, platelet-to-lymphocyte ratio-PLR, lymphocyte monocyte ratio-LMR, systemic immune-inflammation index-SII, prognostic nutritional index-PNI) changes these indices, calculated blood samples taken before surgery. The pCR was evaluated by comparing without pCR. RESULTS Out 932 patients, 188 eligible for Median values baseline SII non-pCR groups 729.3 (595.4-894.8) 869.9(567.2-1145.2, p=0.049). Baseline NLR PLR levels lower group univariate analysis tendency statistical significance. In logistic regression analysis, which NLR, PLR, SII, only <748 found be an independent predictive factor (OR: 0.471, 95% CI; 0.224-0.991, p=0.047). CONCLUSION might receiving LARC. Key Words: Locally cancer, Neoadjuvant chemoradiotherapy, Pathological response, index, Systemic LMR, PNI.